LAAP T-cell therapy (Marker Therapeutics/ Baylor College of Medicine)

N/A

Report date: 2023/01/01 12:03:47

Base Information

Drug NameLAAP T-cell therapy (Marker Therapeutics/ Baylor College of Medicine)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of MedicineMarker Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesMarker TherapeuticsBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A